Transcatheter Heart Valve Replacement Market - Forecasts from 2024 to 2029

The transcatheter heart valve replacement market was valued at US$5.495 billion in 2022.

Aortic valve stenosis can be treated surgically using transcatheter heart valve replacement, which involves swapping out the damaged aortic valve instead of removing it. A sternotomy, or open-heart surgery when the chest is physically opened, is typically required for a valve replacement. The TAVI is carried out through microscopic holes, leaving all of the chest bones in place. Restoring the valve's circulatory system capabilities also entails implanting transcatheter aortic valves or transaortic valves.

Opportunities for the Transcatheter Heart Valve Replacement Market to increase

Transcatheter aortic valve replacement (TAVR) is a minimally invasive technique that is in high demand because of the increased prevalence of aortic valve stenosis (AS), the growing elderly population, and the rising need for less invasive procedures in general. These are some key drivers for the transcatheter heart valve replacement industry. In the United States, 92,000 TAVR valves were implanted in patients in 2021, according to Cardiovascular Business magazine. Major producers of cardiovascular equipment experienced significant revenue losses since the pandemic reduced the number of medical operations overall and affected the supply chain for medical devices.

Growing geriatric population

The key reason driving the expansion of the transcatheter heart valve replacement market is the ageing population, which is more prone to heart illness. Globally, the number of older individuals is rising quickly. Age increases a person's risk of heart failure, and older people are more likely to have these disorders. The market is projected to see increased demand due to the ageing population's increased prevalence of these diseases, which will propel the transcatheter heart valve replacement market growth.

Enhancement in Technology

Significant progress has been achieved in the creation of transcatheter heart valve technology. These developments have produced transcatheter heart valve products that are more dependable, secure, and simple to implant. The development of new biocompatible and long-lasting materials, the use of 3D printing to create custom heart valves, and the advancement of imaging and navigation technologies that enable more precise placement of the heart valve are some of the technological advancements that have fueled the transcatheter heart valve replacement market growth.

The transfemoral surgical approach is gaining popularity

The transfemoral surgical approach is anticipated to dominate the transcatheter heart valve replacement industry due to the advantages of minimally invasive surgery, quicker recovery periods, and reduced healthcare costs. The prosthetic valve is implanted through the femoral artery during the traditional operation using only a small amount of anaesthetic. On the other hand, the transcatheter heart valve replacement market is predicted to have significant growth in the transapical category. The transapical method is advantageous because it facilitates operator mobility during device installation and enables the use of sheaths with larger diameters because the aortic valve and left ventricular apex are nearby.

Increasing patient visits in hospitals

The need for heart disease diagnosis and treatment is anticipated to increase as more people visit hospitals and clinics, which will fuel the transcatheter heart valve replacement market growth throughout the projected period. Additionally, industrial innovation keeps improving prospects. For instance, to broaden the spectrum of therapeutic choices for patients with AS disease, the U.S. FDA authorised Abbott Laboratories, Inc.'s Epic Plus and Epic Plus Supra Stented Tissue Valves in September 2021. Additionally, important manufacturers take on several strategic projects that support the development of the transcatheter heart valve replacement market.

Manufacturers prioritise the creation of a mitral valve product.

Transcatheter mitral valve replacement (TMVR) in heart valve replacement is becoming a new frontier in the industry due to major manufacturers' growing investment in research. Patients' unmet treatment demands and the scarcity of solutions in the transcatheter heart valve replacement industry have prompted several producers to create new TMVR devices and form tactical alliances. For instance, in September 2021, The EpicTM Plus and Epic Plus Supra Stented Tissue Valves from Abbott were recently authorised by the U.S. Food and Drug Administration (FDA), expanding the range of treatment options for patients with aortic or mitral valve disease.

The market for transcatheter heart valve replacement in Europe is anticipated to expand quickly.

During the projection period, there is expected to be an increase in the prevalence of AS diseases and aortic regurgitation in the population, which will fuel Europe's market growth. The transcatheter heart valve replacement market is influenced by several variables, including an increase in heart valve replacement treatments, economic growth, regulatory repercussions, and new product introductions in the EU. For instance, JenaValve Technology, Inc., a producer of TAVR systems, announced the Trilogy heart valve system's introduction in Europe in October 2021. Trilogy's formal European commercial debut began with the operations, which comprised treating both aortic regurgitation1 (AR) and aortic stenosis1 (AS) in several centres around Germany.

Market Expansion Strategies

Increased patient access to TAVR and transcatheter heart valve replacement market growth may result from healthcare systems and insurance companies offering broader payment coverage. However, there is a chance to include intermediate and low-risk individuals in the TAVR indications. Clinical trials are now being conducted by various market players to assess the efficacy and safety of transcatheter heart valve replacement in various patient categories, which has the potential to considerably increase the transcatheter heart valve replacement market.

Market Key Developments

• In December 2022, the newest generation transcatheter aortic valve implantation (TAVI) technology, Navitor, was made accessible by Abbott, a multinational healthcare business, for patients in India who have severe aortic stenosis and are at high or extremely high risk for surgery.
• In September 2022, the FDA granted Edwards Lifesciences permission for its Sapien 3 transcatheter aortic valve, which is equipped with components that the firm says will form the basis of future heart valve implants.
• In January 2022, a Hydra Transcatheter Aortic Heart Valve CE data study was published by Sahajanand Medical Technologies Limited in the American College of Cardiology's Cardiovascular Interventions publication.

Segmentation:

By Product

• Transcatheter Aortic Valve Replacement
• Transcatheter Mitral Valve Repair and Replacement
• Transcatheter Pulmonary Valve Replacement

By Surgical Approach

• Transfemoral Approach
• Transapical Approach
• Others

By End-Use

• Hospitals
• Cath Labs

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others